Belpointe Asset Management LLC Makes New $178,000 Investment in iBio, Inc. (NYSEAMERICAN:IBIO)

Belpointe Asset Management LLC bought a new position in iBio, Inc. (NYSEAMERICAN:IBIO) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 117,750 shares of the biotechnology company’s stock, valued at approximately $178,000. Belpointe Asset Management LLC owned about 0.05% of iBio as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. First Manhattan Co. purchased a new position in iBio in the first quarter worth about $32,000. InterOcean Capital Group LLC lifted its position in shares of iBio by 133.3% during the 1st quarter. InterOcean Capital Group LLC now owns 35,000 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 20,000 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of iBio during the 1st quarter valued at about $55,000. Cubist Systematic Strategies LLC purchased a new position in shares of iBio during the 1st quarter valued at about $60,000. Finally, SG Americas Securities LLC lifted its position in shares of iBio by 266.9% during the 1st quarter. SG Americas Securities LLC now owns 48,413 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 35,217 shares in the last quarter. 19.96% of the stock is currently owned by institutional investors and hedge funds.

Separately, Zacks Investment Research cut iBio from a “buy” rating to a “hold” rating in a research report on Tuesday, July 20th.

NYSEAMERICAN IBIO opened at $1.14 on Wednesday. The company has a market cap of $248.35 million, a PE ratio of -1.87 and a beta of -6.24. The company has a debt-to-equity ratio of 0.30, a quick ratio of 17.60 and a current ratio of 17.67. iBio, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $2.83.

iBio Profile

iBio, Inc is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. The firm operates through the iBio, Inc and iBio CDMO business segments. The company was founded by Robert B.

Featured Story: How do candlesticks reflect price movement?

Want to see what other hedge funds are holding IBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iBio, Inc. (NYSEAMERICAN:IBIO).

Institutional Ownership by Quarter for iBio (NYSEAMERICAN:IBIO)

Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.